Daré Bioscience Inc. reported its financial results for the third quarter ended September 30, 2025, and provided a corporate update. The company announced that DARE to PLAY™ Sildenafil Cream is on track to launch before year-end via the 503B compounding pathway, which is expected to generate near-term product revenue. The company also reported a positive interim DSMB outcome for the Ovaprene® Phase 3 study, supporting continued enrollment. Daré Bioscience highlighted the advancement of multiple grant-funded programs, including those addressing HPV and long-acting as well as non-hormonal contraception. The company expects four women's health products to become commercially available over the next two years. Following the launch of DARE to PLAY™ Sildenafil Cream, commercialization of DARE to RESTORE™ vaginal probiotics in the consumer health market is targeted, and DARE to RECLAIM™ monthly hormone therapy via the 503B compounding pathway is planned for early 2027. Daré Bioscience stated that DARE to RECLAIM™ will establish its entry into the estimated $4.5 billion compounded hormone therapy market while the company continues to pursue FDA approval opportunities. The company encouraged investors to review its Form 10-Q for detailed financial information, results of operations, liquidity, capital resources, and risk factors.